Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
J Immunother Precis Oncol. 2024;7(4):255-262 - PMID: 39524465 - PMCID: PMC11541930 - DOI: 10.36401/JIPO-24-6
Morita S, Lei PJ, Shigeta K, Ando T, Kobayashi T, Kikuchi H, Matsui A, Huang P, Pittet MJ, Duda DG
Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma.
Cancer Immunol Res. 2024;:ePub - PMID: 39514263 - DOI: 10.1158/2326-6066.CIR-24-0324
Pal R, Krishnamoorthy M, Matsui A, Kang H, Morita S, Taniguchi H, Kobayashi T, Morita A, Choi HS, Duda DG, Kumar ATN
Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity.
Cancer Res. 2024;:ePub - PMID: 39514403 - DOI: 10.1158/0008-5472.CAN-24-0880
LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO
Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma.
Oncology. 2024;:1-8 - PMID: 39427654 - DOI: 10.1159/000541250
Wu B, Tapadar S, Ruan Z, Sun CQ, Arnold RS, Johnston A, Olugbami JO, Arunsi U, Gaul DA, Petros JA, Kobayashi T, Duda DG, Oyelere AK
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
ACS Pharmacol Transl Sci. 2024;7(10):3155-3169 - PMID: 39416967 - PMCID: PMC11475281 - DOI: 10.1021/acsptsci.4c00358
Park RJ, Parikh M, Pappas L, Sade-Feldman M, Kulkarni AS, Bi L, LaSalle TJ, Galway A, Kuhlman C, Blaszkowsky LS, Meyerhardt JA, Enzinger PC, Biller L, Allen JN, Kagey MH, Baum J, Sirard C, Duda DG, Zhu AX, Abrams TA, Hacohen N, Ting DT, Mehta A, Goyal L
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
medRxiv. 2024;:ePub - PMID: 39417106 - PMCID: PMC11483019 - DOI: 10.1101/2024.10.08.24315092
Ho AY, Shiao S, Kobald SA, Chen J, Duda DG, Ly A, Bossuyt V, Cho HL, Arnold B, Knott S, Gupta GP, McAndrew P, Karlan S, Tighiouart M, Muzikansky A, Basho R, McArthur H
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J Clin Oncol. 2024;42(36):4282-4293 - PMID: 39298718 - DOI: 10.1200/JCO.24.00003
Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Cancer Biomark. 2024;41(1):83-91 - PMID: 39269823 - PMCID: PMC11491993 - DOI: 10.3233/CBM-230431
Sivanand S, Gultekin Y, Winter PS, Vermeulen SY, Tchourine KM, Abbott KL, Danai LV, Gourgue F, Do BT, Crowder K, Kunchok T, Lau AN, Darnell AM, Jefferson A, Morita S, Duda DG, Aguirre AJ, Wolpin BM, Henning N, Spanoudaki V, Maiorino L, Irvine DJ, Yilmaz OH, Lewis CA, Vitkup D, Shalek AK, Vander Heiden MG
Cancer tissue of origin constrains the growth and metabolism of metastases.
Nat Metab. 2024;6(9):1668-1681 - PMID: 39160333 - PMCID: PMC11450831 - DOI: 10.1038/s42255-024-01105-9
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Mol Cancer. 2024;23(1):156 - PMID: 39095771 - PMCID: PMC11295620 - DOI: 10.1186/s12943-024-02060-5
Wu B, Tapadar S, Ruan Z, Sun CQ, Arnold RS, Olugbami JO, Johnston A, Arunsi U, Gaul DA, Petros JA, Kobayashi T, Duda DG, Oyelere AK
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
bioRxiv. 2024;:ePub - PMID: 38585757 - PMCID: PMC10996603 - DOI: 10.1101/2024.03.27.587062
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
medRxiv. 2024;:ePub - PMID: 38559070 - PMCID: PMC10980136 - DOI: 10.1101/2024.03.14.24304306
Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024;11:455-461 - PMID: 38463542 - PMCID: PMC10921889 - DOI: 10.2147/JHC.S452564
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin SM, Matsui A, Hernandez A, Pu Z, Halvorsen S, Lei PJ, Datta M, Zhu L, Ruan Z, Shi L, Staiculescu D, Inoue K, Munn LL, Fukumura D, Huang P, Sassi S, Bardeesy N, Ho WJ, Jain RK, Duda DG
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486
Saylor PJ, Kozin SV, Matsui A, Goldberg SI, Aoki S, Shigeta K, Mamessier E, Smith MR, Dror Michaelson M, Lee RJ, Duda DG
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Radiother Oncol. 2024;192:110091 - PMID: 38224917 - PMCID: PMC10905770 - DOI: 10.1016/j.radonc.2024.110091
15